The University of Pittsburgh has become one of 12 organizations nationwide selected to participate in a COVID-19 mixed booster shot trial and is currently accepting participants.

The trial, which is being done by the National Institute of Allergy and Infectious Diseases, will have fully vaccinated adults receive a third dose of the vaccine — a booster — to study the safety and immune response.

People wishing to enroll in the trial must be over the age of 18, be vaccinated and have no known history of contracting COVID-19.

The study will be broken up into two groups; the first will be about 150 adults who received one of the three vaccines available in the U.S. They will receive the booster — of the same vaccine or a different one, according to the clinical trial information — between 12 and 20 weeks after becoming fully vaccinated.

Advertise with us

The second group will be about 250 adults who are not vaccinated and have no known history of contracting the virus. Volunteers in this group will receive two doses of the Moderna vaccine as prescribed. Twelve to 20 weeks later, they will receive a booster dose.

Over the next year, the volunteers will provide blood samples used to study their immune response. If a participant were to contract COVID-19 during the study, researchers will look into whether the infection was caused by a variant, like the quickly spreading delta variant.

Other combinations of vaccines may be included later in the research, according to the university.

“As more and more COVID-19 variants are identified, we need to figure out how we, as a community, can stay protected,” said Dr. Judy Martin, a professor of pediatrics at the Pitt’s School of Medicine and a member of Pitt’s Center for Vaccine Research. “The study’s design is not to show whether we need booster shots. Its focus is identifying which vaccine combinations are safe and provide the most protection against the virus that causes COVID-19 and its variants.”

Dr. Martin is also the principal investigator for Pitt’s trial.

The participants will be studied for a year, but initial results are expected toward the end of this summer, the university said.